首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4457篇
  免费   383篇
  国内免费   1篇
  2023年   21篇
  2022年   34篇
  2021年   107篇
  2020年   60篇
  2019年   107篇
  2018年   99篇
  2017年   95篇
  2016年   146篇
  2015年   250篇
  2014年   258篇
  2013年   288篇
  2012年   368篇
  2011年   373篇
  2010年   209篇
  2009年   196篇
  2008年   262篇
  2007年   288篇
  2006年   230篇
  2005年   229篇
  2004年   164篇
  2003年   204篇
  2002年   185篇
  2001年   50篇
  2000年   29篇
  1999年   47篇
  1998年   46篇
  1997年   35篇
  1996年   26篇
  1995年   24篇
  1994年   28篇
  1993年   33篇
  1992年   23篇
  1991年   24篇
  1990年   22篇
  1989年   18篇
  1988年   30篇
  1987年   14篇
  1986年   17篇
  1985年   25篇
  1984年   17篇
  1983年   10篇
  1982年   10篇
  1978年   7篇
  1977年   9篇
  1976年   11篇
  1975年   12篇
  1973年   12篇
  1972年   12篇
  1971年   13篇
  1967年   9篇
排序方式: 共有4841条查询结果,搜索用时 218 毫秒
91.
92.
Identification of driver mutations in lung adenocarcinoma has led to development of targeted agents that are already approved for clinical use or are in clinical trials. Therefore, the number of biomarkers that will be needed to assess is expected to rapidly increase. This calls for the implementation of methods probing the mutational status of multiple genes for inoperable cases, for which limited cytological or bioptic material is available. Cytology specimens from 38 lung adenocarcinomas were subjected to the simultaneous assessment of 504 mutational hotspots of 22 lung cancer-associated genes using 10 nanograms of DNA and Ion Torrent PGM next-generation sequencing. Thirty-six cases were successfully sequenced (95%). In 24/36 cases (67%) at least one mutated gene was observed, including EGFR, KRAS, PIK3CA, BRAF, TP53, PTEN, MET, SMAD4, FGFR3, STK11, MAP2K1. EGFR and KRAS mutations, respectively found in 6/36 (16%) and 10/36 (28%) cases, were mutually exclusive. Nine samples (25%) showed concurrent alterations in different genes. The next-generation sequencing test used is superior to current standard methodologies, as it interrogates multiple genes and requires limited amounts of DNA. Its applicability to routine cytology samples might allow a significant increase in the fraction of lung cancer patients eligible for personalized therapy.  相似文献   
93.
94.
The outcome of infection by Mycobacterium tuberculosis (Mtb) depends greatly on how the host responds to the bacteria and how the bacteria manipulates the host, which is facilitated by protein–protein interactions. Thus, to understand this process, there is a need for elucidating protein interactions between human and Mtb, which may enable us to characterize specific molecular mechanisms allowing the bacteria to persist and survive under different environmental conditions. In this work, we used the interologs method based on experimentally verified intra-species and inter-species interactions to predict human-Mtb functional interactions. These interactions were further filtered using known human-Mtb interactions and genes that are differentially expressed during infection, producing 190 interactions. Further analysis of the subcellular location of proteins involved in these human-Mtb interactions confirms feasibility of these interactions. We also conducted functional analysis of human and Mtb proteins involved in these interactions, checking whether these proteins play a role in infection and/or disease, and enriching Mtb proteins in a previously predicted list of drug targets. We found that the biological processes of the human interacting proteins suggested their involvement in apoptosis and production of nitric oxide, whereas those of the Mtb interacting proteins were relevant to the intracellular environment of Mtb in the host. Mapping these proteins onto KEGG pathways highlighted proteins belonging to the tuberculosis pathway and also suggested that Mtb proteins might use the host to acquire nutrients, which is in agreement with the intracellular lifestyle of Mtb. This indicates that these interactions can shed light on the interplay between Mtb and its human host and thus, contribute to the process of designing novel drugs with new biological mechanisms of action.  相似文献   
95.
96.
97.
ErbB-3 (HER-3) receptor is involved in tumor progression and resistance to therapy. Development of specific inhibitors impairing the activity of ErbB-3 is an attractive tool for cancer therapeutics. MP-RM-1, a murine monoclonal antibody targeting human ErbB-3, has shown anticancer activity in preclinical models. With the aim to provide novel candidates for clinical use, we have successfully generated a humanized version of MP-RM-1. The humanized antibody, named EV20, abrogates both ligand-dependent and ligand-independent receptor signaling of several tumor cell types, strongly promotes ErbB-3 down-regulation, and efficiently and rapidly internalizes into tumor cells. Furthermore, treatment with EV20 significantly inhibits growth of xenografts originating from prostatic, ovarian, and pancreatic cancers as well as melanoma in nude mice. In conclusion, we provide a novel candidate for ErbB-3-targeted cancer therapy.  相似文献   
98.
In the present study, we used a functional proteomic approach to identify Annexin A1 (Anxa1) interacting proteins in the Philadelphia‐positive KCL22 cell line. We focused on Anxa1 because it is one of the major proteins upregulated in imatinib‐sensitive KCL22S cells versus imatinib‐resistant KCL22R. Our proteomic strategy revealed 21 interactors. Bioinformatic analysis showed that most of these proteins are involved in cell death processes. Among the proteins identified, we studied the interaction of Anxa1 with two phosphatases, Shp1 and Shp2, which were recently identified as biomarkers of imatinib sensitivity in patients affected by chronic myeloid leukemia. Our data open new perspectives in the search for annexin‐mediated signaling pathways and may shed light on mechanisms of resistance to imatinib that are unrelated to Bcr‐Abl activity. All mass spectrometry data have been deposited in the ProteomeXchange with identifier PXD000030.  相似文献   
99.
The niche of introduced species and that of native ones may overlap, thus causing detrimental effects on the latter through competitive interactions. We used radio telemetry to investigate habitat partitioning during the active period by the introduced American eastern cottontail (Sylvilagus floridanus) and the native European hare (Lepus europaeus) in sympatric conditions. Home ranges of cottontails varied from 1.1–2.2 ha in autumn to 3.0–3.6 ha in summer. In hares, home ranges were 30.5–33.8 ha in summer and increased to 49.5–85.9 ha in winter. Both species used an overall area composed of about 27% of natural habitats (i.e., meadows, woodlands, shrubby habitats, shores, and uncultivated land) and over 70% of field crops. The coexistence of the two species appeared to be facilitated by habitat partitioning. Habitat use of cottontails was characterized by a preference for natural habitats at the study area level as well as within the home ranges, while hares showed a preference for crop fields at both spatial scales and a seasonal selection of meadows within home ranges. Habitat overlap measured with the Pianka index was 0.57–0.64 in autumn and winter, and increased in summer and spring to 0.73–0.78. Our results provide evidence of different resource selection strategies adopted by these two sympatric lagomorph species. Hare populations are often found in agricultural landscapes at low-densities, while cottontails are currently spreading throughout Northern Italy to such an extent that an eradication programme appears unfeasible. In this situation, conservation measures for hares and other species should also take into consideration the presence or possible arrival of cottontails. Habitat restoration measures that would increase the amount of fallow lands and shrublands may favour cottontails more than hares. In areas where introduced lagomorphs are present, the necessity of natural open landscapes for hares may be better faced by increasing the presence of meadows, that are seasonally used by hares and not by cottontails.  相似文献   
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号